Rabies Vaccine

Summary

Rabies Vaccine (CHEMBL2107909) is a phase-3 clinical-stage vaccine component; indicated across 5 conditions including malaria and rhabdoviridae infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Vaccine component
• Indications: 5 conditions
• Clinical trials: 39

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107909
Name	Rabies Vaccine
Type	Vaccine component
Max phase	3

Also known as: Rabies vaccine, Rabies vaccine adsorbed, Rabies vaccines, RABIES VACCINE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
malaria	3	MONDO:0005136	EFO:0001068
Rhabdoviridae infectious disease	3	MONDO:0005944	EFO:0007469
Plasmodium falciparum malaria	2	MONDO:0005920	EFO:0007444
HIV infectious disease	2	MONDO:0005109	EFO:0000764

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 39.

Phase distribution

Phase	Trials
PHASE2	10
PHASE3	9
PHASE4	6
Not specified	5
PHASE1/PHASE2	4
PHASE1	4
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01173302	PHASE4	UNKNOWN	Persistence of Rabies Antibody 1-5 Years After the Post-exposure Prophylaxis With Vero Cell Antirabies Vaccine and Antibody Response to a Single Booster Dose
NCT01827917	PHASE4	COMPLETED	The Protection Effect of Speeda® Rabies Vaccine for Human Use
NCT02374814	PHASE4	COMPLETED	Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis
NCT02564471	PHASE4	COMPLETED	Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.
NCT03557008	PHASE4	COMPLETED	Responses to Rabies Vaccine in Adults With or Without Antibiotics
NCT05453487	PHASE4	UNKNOWN	Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine
NCT04704830	PHASE3	ACTIVE_NOT_RECRUITING	R21/Matrix-M in African Children Against Clinical Malaria
NCT07055893	PHASE3	NOT_YET_RECRUITING	Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen
NCT07345208	PHASE2/PHASE3	NOT_YET_RECRUITING	Safety and Immunogenicity of ID vs IM Rabies Vaccine
NCT00345319	PHASE3	COMPLETED	Purified Rabies Vaccine for Human Use (Chick-embryo Cell)
NCT01107275	PHASE3	COMPLETED	Early Rabies Vaccine Immunization in Primary School Children
NCT01466387	PHASE3	COMPLETED	A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
NCT02177032	PHASE3	COMPLETED	Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age
NCT04644484	PHASE3	COMPLETED	A Phase III Clinical Study to Evaluate SYN023’s Efficacy and Safety
NCT05549908	PHASE3	COMPLETED	Vaccine Prevention of Rabies Adopts 4-shot Immunization Method
NCT05846568	PHASE3	COMPLETED	Study to Evaluate GR1801’s Efficacy and Safety
NCT05790889	PHASE1/PHASE2	RECRUITING	A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.
NCT06799234	PHASE2	ACTIVE_NOT_RECRUITING	Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)
NCT07445815	PHASE2	NOT_YET_RECRUITING	A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody
NCT00031070	PHASE2	COMPLETED	Increasing HAART-Induced Immune Restoration With Cyclosporine
NCT00460525	PHASE2	COMPLETED	Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
NCT00703521	PHASE2	COMPLETED	Rabies Immunization Concomitant With JEV in Children
NCT01635647	PHASE1/PHASE2	COMPLETED	A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso
NCT01658696	PHASE2	COMPLETED	Efficacy of Candidate Malaria Vaccines in Senegalese Adults
NCT01666925	PHASE2	COMPLETED	Efficacy of Malaria Vaccines in Kenyan Adults
NCT02276625	PHASE2	UNKNOWN	One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding
NCT03276962	PHASE2	COMPLETED	Efficacy, Safety and Immunogenicity Study of GSK Biologicals’ Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
NCT03896724	PHASE1/PHASE2	COMPLETED	Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
NCT03961555	PHASE2	COMPLETED	Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
NCT04495569	PHASE1/PHASE2	COMPLETED	A Bridging Study of the SYN023 on Healthy Adult Subjects
NCT00703066	PHASE1	UNKNOWN	Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years
NCT03435874	PHASE1	COMPLETED	Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania
NCT04019444	PHASE1	COMPLETED	Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects
NCT07342257	PHASE1	COMPLETED	SYN023 With Rabies Vaccine in Healthy Pediatric Subjects
NCT06180447	Not specified	ACTIVE_NOT_RECRUITING	Peri-conceptional or Pregnancy Exposure of Vaccination and the Risk of Adverse Pregnancy Outcomes
NCT01641315	Not specified	COMPLETED	Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins
NCT02339896	Not specified	UNKNOWN	Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children
NCT02547727	Not specified	UNKNOWN	Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults
NCT04829630	Not specified	COMPLETED	Immunity Persistence After Abridged Intradermal Rabies PEP

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).